Redmile Group LLC lifted its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 2.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 698,392 shares of the biotechnology company’s stock after purchasing an additional 16,500 shares during the period. Redmile Group LLC owned 1.89% of CytomX Therapeutics worth $10,825,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the stock. FMR LLC increased its holdings in shares of CytomX Therapeutics by 0.6% in the second quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock valued at $85,444,000 after purchasing an additional 34,732 shares in the last quarter. Perceptive Advisors LLC boosted its stake in CytomX Therapeutics by 65.7% in the first quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock valued at $26,434,000 after acquiring an additional 606,896 shares during the last quarter. Vanguard Group Inc. boosted its stake in CytomX Therapeutics by 12.2% in the second quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock valued at $14,323,000 after acquiring an additional 100,607 shares during the last quarter. EcoR1 Capital LLC bought a new position in CytomX Therapeutics in the first quarter valued at approximately $13,729,000. Finally, Numeric Investors LLC bought a new position in CytomX Therapeutics in the second quarter valued at approximately $9,730,000. 59.97% of the stock is owned by institutional investors and hedge funds.
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded up 2.20% during midday trading on Tuesday, hitting $20.95. 223,812 shares of the company were exchanged. CytomX Therapeutics, Inc. has a one year low of $9.85 and a one year high of $24.67. The firm’s 50 day moving average price is $18.43 and its 200 day moving average price is $15.80. The firm’s market capitalization is $772.36 million.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. Analysts forecast that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current fiscal year.
A number of equities analysts have issued reports on the stock. BidaskClub cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, June 28th. Finally, Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Monday. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $31.43.
In other news, CEO Sean A. Mccarthy sold 19,120 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $24.13, for a total transaction of $461,365.60. Following the completion of the transaction, the chief executive officer now directly owns 23,365 shares in the company, valued at approximately $563,797.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Robert I. Tepper sold 24,777 shares of the stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The disclosure for this sale can be found here. Insiders sold a total of 177,794 shares of company stock valued at $3,806,089 over the last 90 days. 8.00% of the stock is currently owned by corporate insiders.
CytomX Therapeutics Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with our FREE daily email newsletter.